Jennifer Clarke, MD, MPH
Professor
Neurology
School of Medicine

Jennifer L. Clarke, MD, MPH Professor of Clinical Neurology and Neurological Surgery Division of Neuro-Oncology Principal Investigator, Brain Tumor Research Center

Education & Training

Show all (7) Hide

• Diversity, Equity, and Inclusion Champion Training University of California 2019
• Neuro Oncology Fellowship Memorial Sloan-Kettering Cancer Center 2008
• Neurology University of California, San Francisco 2006
• Intern, Medicine St. Mary's Medical Center, San Francisco 2003
• MD University of California, San Francisco 2002
• MPH Health Policy and Management University of California, Berkeley 2001
• B.S. Chemistry California Institute of Technology 1995

Websites

Show all (2) Hide

• Clinical Profile at UCSF Medical Center (ucsfhealth.org)
• Profile at UCSF Neurosurgery (neurosurgery.ucsf.edu)

Publications (73)

Top publication keywords:
Neoplasms, NeuroepithelialGliomaIsocitrate DehydrogenaseQuinazolinesChemoradiotherapyCamptothecinAntineoplastic Agents, PhytogenicGlioblastomaCancer VaccinesMeningeal CarcinomatosisAntineoplastic Agents, AlkylatingDacarbazineBrain NeoplasmsAntibodies, Monoclonal, HumanizedNeoplasm Recurrence, Local

• A combinatory vaccine with IMA950 plus varlilumab promotes effector memory T-cell differentiation in the peripheral blood of patients with low-grade gliomas.
  Neuro-oncology 2024 Saijo A, Ogino H, Butowski NA, Tedesco MR, Gibson D, Watchmaker PB, Okada K, Wang AS, Shai A, Salazar AM, Molinaro AM, Rabbitt JE, Shahin M, Perry A, Clarke JL, Taylor JW, Daras M, Oberheim Bush NA, …
• Advanced Hyperpolarized 13C Metabolic Imaging Protocol for Patients with Gliomas: A Comprehensive Multimodal MRI Approach.
  Cancers 2024 Autry AW, Vaziri S, Gordon JW, Chen HY, Kim Y, Dang D, LaFontaine M, Noeske R, Bok R, Villanueva-Meyer JE, Clarke JL, Oberheim Bush NA, Chang SM, Xu D, Lupo JM, Larson PEZ, Vigneron DB, Li Y
• Author Correction: Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial.
  Nature medicine 2024 Mellinghoff IK, Lu M, Wen PY, Taylor JW, Maher EA, Arrillaga-Romany I, Peters KB, Ellingson BM, Rosenblum MK, Chun S, Le K, Tassinari A, Choe S, Toubouti Y, Schoenfeld S, Pandya SS, Hassan I, Steelman…
• "De novo replication repair deficient glioblastoma, IDH-wildtype" is a distinct glioblastoma subtype in adults that may benefit from immune checkpoint blockade.
  Acta neuropathologica 2023 Hadad S, Gupta R, Oberheim Bush NA, Taylor JW, Villanueva-Meyer JE, Young JS, Wu J, Ravindranathan A, Zhang Y, Warrier G, McCoy L, Shai A, Pekmezci M, Perry A, Bollen AW, Phillips JJ, Braunstein SE, …
• Activity of a first-in-class oral HIF2-alpha inhibitor, PT2385, in patients with first recurrence of glioblastoma.
  Journal of neuro-oncology 2023 Strowd R, Ellingson B, Raymond C, Yao J, Wen PY, Ahluwalia M, Piotrowski A, Desai A, Clarke JL, Lieberman FS, Desideri S, Nabors LB, Ye X, Grossman S

Show all (68 more) Hide

• Multi-parametric hyperpolarized 13C/1H imaging reveals Warburg-related metabolic dysfunction and associated regional heterogeneity in high-grade human gliomas.
  NeuroImage. Clinical 2023 Autry AW, Vaziri S, LaFontaine M, Gordon JW, Chen HY, Kim Y, Villanueva-Meyer JE, Molinaro A, Clarke JL, Oberheim Bush NA, Xu D, Lupo JM, Larson PEZ, Vigneron DB, Chang SM, Li Y
• Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial.
  Nature medicine 2023 Mellinghoff IK, Lu M, Wen PY, Taylor JW, Maher EA, Arrillaga-Romany I, Peters KB, Ellingson BM, Rosenblum MK, Chun S, Le K, Tassinari A, Choe S, Toubouti Y, Schoenfeld S, Pandya SS, Hassan I, Steelman…
• Evaluation of cross-platform compatibility of a DNA methylation-based glucocorticoid response biomarker.
  Clinical epigenetics 2022 Tang E, Wiencke JK, Warrier G, Hansen H, McCoy L, Rice T, Bracci PM, Wrensch M, Taylor JW, Clarke JL, Koestler DC, Salas LA, Christensen BC, Kelsey KT, Molinaro AM
• Prospective genomically guided identification of "early/evolving" and "undersampled" IDH-wildtype glioblastoma leads to improved clinical outcomes.
  Neuro-oncology 2022 Zhang Y, Lucas CG, Young JS, Morshed RA, McCoy L, Oberheim Bush NA, Taylor JW, Daras M, Butowski NA, Villanueva-Meyer JE, Cha S, Wrensch M, Wiencke JK, Lee JC, Pekmezci M, Phillips JJ, Perry A, Bollen…
• Assessment of higher-order singular value decomposition denoising methods on dynamic hyperpolarized [1-13C]pyruvate MRI data from patients with glioma.
  NeuroImage. Clinical 2022 Vaziri S, Autry AW, Lafontaine M, Kim Y, Gordon JW, Chen HY, Hu JY, Lupo JM, Chang SM, Clarke JL, Villanueva-Meyer JE, Bush NAO, Xu D, Larson PEZ, Vigneron DB, Li Y
• Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.
  Acta neuropathologica 2022 Lucas CG, Sloan EA, Gupta R, Wu J, Pratt D, Vasudevan HN, Ravindranathan A, Barreto J, Williams EA, Shai A, Whipple NS, Bruggers CS, Maher O, Nabors B, Rodriguez M, Samuel D, Brown M, Carmichael J, Lu…
• Pre-surgery immune profiles of adult glioma patients.
  Journal of neuro-oncology 2022 Bracci PM, Rice T, Hansen HM, Francis SS, Lee S, McCoy LS, Shrestha PP, Warrier G, Clarke JL, Molinaro AM, Taylor JW, Wiencke JK, Wrensch MR
• Circulating Immune Cell and Outcome Analysis from the Phase II Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2022 Nayak L, Standifer N, Dietrich J, Clarke JL, Dunn GP, Lim M, Cloughesy T, Gan HK, Flagg E, George E, Gaffey S, Hayden J, Holcroft C, Wen PY, Macri M, Park AJ, Ricciardi T, Ryan A, Schwarzenberger P, …
• Combining radiomics and deep convolutional neural network features from preoperative MRI for predicting clinically relevant genetic biomarkers in glioblastoma.
  Neuro-oncology advances 2022 Calabrese E, Rudie JD, Rauschecker AM, Villanueva-Meyer JE, Clarke JL, Solomon DA, Cha S
• Interactions of Age and Blood Immune Factors and Noninvasive Prediction of Glioma Survival.
  Journal of the National Cancer Institute 2022 Molinaro AM, Wiencke JK, Warrier G, Koestler DC, Chunduru P, Lee JY, Hansen HM, Lee S, Anguiano J, Rice T, Bracci PM, McCoy L, Salas LA, Christensen BC, Wrensch M, Kelsey KT, Taylor JW, Clarke JL
• Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T cell response in low-grade gliomas.
  The Journal of clinical investigation 2022 Ogino H, Taylor JW, Nejo T, Gibson D, Watchmaker PB, Okada K, Saijo A, Tedesco MR, Shai A, Wong CM, Rabbitt JE, Olin MR, Moertel CL, Nishioka Y, Salazar AM, Molinaro AM, Phillips JJ, Butowski NA, …
• EWSR1-BEND2 fusion defines an epigenetically distinct subtype of astroblastoma.
  Acta neuropathologica 2021 Lucas CG, Gupta R, Wu J, Shah K, Ravindranathan A, Barreto J, Gener M, Ginn KF, Prall OWJ, Xu H, Kee D, Ko HS, Yaqoob N, Zia N, Florez A, Cha S, Perry A, Clarke JL, Chang SM, Berger MS, Solomon DA
• Diffuse hemispheric glioma, H3 G34-mutant: Genomic landscape of a new tumor entity and prospects for targeted therapy.
  Neuro-oncology 2021 Lucas CG, Mueller S, Reddy A, Taylor JW, Oberheim Bush NA, Clarke JL, Chang SM, Gupta N, Berger MS, Perry A, Phillips JJ, Solomon DA
• Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas.
  Neuro-oncology 2021 Yu Y, Villanueva-Meyer J, Grimmer MR, Hilz S, Solomon DA, Choi S, Wahl M, Mazor T, Hong C, Shai A, Phillips JJ, Wainer BH, McDermott M, Haas-Kogan D, Taylor JW, Butowski N, Clarke JL, Berger MS, …
• A multicenter analysis of the prognostic value of histone H3 K27M mutation in adult high-grade spinal glioma.
  Journal of neurosurgery. Spine 2021 Akinduro OO, Garcia DP, Higgins DMO, Vivas-Buitrago T, Jentoft M, Solomon DA, Daniels DJ, Pennington Z, Sherman WJ, Delgardo M, Bydon M, Kalani MA, Zanazzi G, Tsankova N, Bendok BR, McCormick PC, …
• Low-grade glioneuronal tumors with FGFR2 fusion resolve into a single epigenetic group corresponding to 'Polymorphous low-grade neuroepithelial tumor of the young'.
  Acta neuropathologica 2021 Gupta R, Lucas CG, Wu J, Barreto J, Shah K, Simon IB, Casavilca-Zambrano S, Brathwaite C, Zhou H, Caccamo D, Gilani A, Kleinschmidt-DeMasters BK, Lee JC, Perry A, Clarke JL, Chang SM, Berger MS, …
• Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2021 Mellinghoff IK, Penas-Prado M, Peters KB, Burris HA, Maher EA, Janku F, Cote GM, de la Fuente MI, Clarke JL, Ellingson BM, Chun S, Young RJ, Liu H, Choe S, Lu M, Le K, Hassan I, Steelman L, Pandya SS,…
• Proof-of-concept single-arm trial of bevacizumab therapy for brain arteriovenous malformation.
  BMJ neurology open 2021 Muster R, Ko N, Smith W, Su H, Dickey MA, Nelson J, McCulloch CE, Sneed PK, Clarke JL, Saloner DA, Eisenmenger L, Kim H, Cooke DL
• Current Advances in Immunotherapy for Glioblastoma.
  Current oncology reports 2021 Mende AL, Schulte JD, Okada H, Clarke JL
• Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2020 Nayak L, Molinaro AM, Peters K, Clarke JL, Jordan JT, de Groot J, Nghiemphu L, Kaley T, Colman H, McCluskey C, Gaffey S, Smith TR, Cote DJ, Severgnini M, Yearley JH, Zhao Q, Blumenschein WM, Duda DG, …
• Clinical, radiologic, and genetic characteristics of histone H3 K27M-mutant diffuse midline gliomas in adults.
  Neuro-oncology advances 2020 Schulte JD, Buerki RA, Lapointe S, Molinaro AM, Zhang Y, Villanueva-Meyer JE, Perry A, Phillips JJ, Tihan T, Bollen AW, Pekmezci M, Butowski N, Oberheim Bush NA, Taylor JW, Chang SM, Theodosopoulos P,…
• Comprehensive analysis of diverse low-grade neuroepithelial tumors with FGFR1 alterations reveals a distinct molecular signature of rosette-forming glioneuronal tumor.
  Acta neuropathologica communications 2020 Lucas CG, Gupta R, Doo P, Lee JC, Cadwell CR, Ramani B, Hofmann JW, Sloan EA, Kleinschmidt-DeMasters BK, Lee HS, Wood MD, Grafe M, Born D, Vogel H, Salamat S, Puccetti D, Scharnhorst D, Samuel D, …
• Characterization of serial hyperpolarized 13C metabolic imaging in patients with glioma.
  NeuroImage. Clinical 2020 Autry AW, Gordon JW, Chen HY, LaFontaine M, Bok R, Van Criekinge M, Slater JB, Carvajal L, Villanueva-Meyer JE, Chang SM, Clarke JL, Lupo JM, Xu D, Larson PEZ, Vigneron DB, Li Y
• Treatment-induced lesions in newly diagnosed glioblastoma patients undergoing chemoradiotherapy and heat-shock protein vaccine therapy.
  Journal of neuro-oncology 2019 Alcaide-Leon P, Luks TL, Lafontaine M, Lupo JM, Okada H, Clarke JL, Villanueva-Meyer JE
• Recurrent non-canonical histone H3 mutations in spinal cord diffuse gliomas.
  Acta neuropathologica 2019 Sloan EA, Cooney T, Oberheim Bush NA, Buerki R, Taylor J, Clarke JL, Torkildson J, Kline C, Reddy A, Mueller S, Banerjee A, Butowski N, Chang S, Mummaneni PV, Chou D, Tan L, Theodosopoulos P, …
• Reirradiation of recurrent high-grade glioma and development of prognostic scores for progression and survival.
  Neuro-oncology practice 2019 Chapman CH, Hara JH, Molinaro AM, Clarke JL, Oberheim Bush NA, Taylor JW, Butowski NA, Chang SM, Fogh SE, Sneed PK, Nakamura JL, Raleigh DR, Braunstein SE
• Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma.
  Nature medicine 2019 Cloughesy TF, Mochizuki AY, Orpilla JR, Hugo W, Lee AH, Davidson TB, Wang AC, Ellingson BM, Rytlewski JA, Sanders CM, Kawaguchi ES, Du L, Li G, Yong WH, Gaffey SC, Cohen AL, Mellinghoff IK, Lee EQ, …
• Risk factors of radiotherapy-induced cerebral microbleeds and serial analysis of their size compared with white matter changes: A 7T MRI study in 113 adult patients with brain tumors.
  Journal of magnetic resonance imaging : JMRI 2019 Morrison MA, Hess CP, Clarke JL, Butowski N, Chang SM, Molinaro AM, Lupo JM
• Attitudes toward fertility and fertility preservation in women with glioma.
  Neuro-oncology practice 2018 Stiner RK, Clarke JL, Sinha N, Chan J, Letourneau JM, Niemasik EE, Rabbitt JE, Chang SM, Butowski NA, Prados MD, Rosen MP
• Phase-2 trial of palbociclib in adult patients with recurrent RB1-positive glioblastoma.
  Journal of neuro-oncology 2018 Taylor JW, Parikh M, Phillips JJ, James CD, Molinaro AM, Butowski NA, Clarke JL, Oberheim-Bush NA, Chang SM, Berger MS, Prados M
• The genetic landscape of ganglioglioma.
  Acta neuropathologica communications 2018 Pekmezci M, Villanueva-Meyer JE, Goode B, Van Ziffle J, Onodera C, Grenert JP, Bastian BC, Chamyan G, Maher OM, Khatib Z, Kleinschmidt-DeMasters BK, Samuel D, Mueller S, Banerjee A, Clarke JL, Cooney …
• Genomic analysis of the origins and evolution of multicentric diffuse lower-grade gliomas.
  Neuro-oncology 2018 Hayes J, Yu Y, Jalbert LE, Mazor T, Jones LE, Wood MD, Walsh KM, Bengtsson H, Hong C, Oberndorfer S, Roetzer T, Smirnov IV, Clarke JL, Aghi MK, Chang SM, Nelson SJ, Woehrer A, Phillips JJ, Solomon DA,…
• Short term dynamics of the sputum microbiome among COPD patients.
  PloS one 2018 Sinha R, Weissenburger-Moser LA, Clarke JL, Smith LM, Heires AJ, Romberger DJ, LeVan TD
• Survivorship care planning in neuro-oncology.
  Neuro-oncology practice 2018 Leeper HE, Acquaye AA, Bell S, Clarke JL, Forst D, Laack NN, Link MJ, Taylor JW, Armstrong TS
• Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive Glioblastoma.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2017 Byron SA, Tran NL, Halperin RF, Phillips JJ, Kuhn JG, de Groot JF, Colman H, Ligon KL, Wen PY, Cloughesy TF, Mellinghoff IK, Butowski NA, Taylor JW, Clarke JL, Chang SM, Berger MS, Molinaro AM, …
• Probing the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in gliomas: A phase 2 study of everolimus for recurrent adult low-grade gliomas.
  Cancer 2017 Wahl M, Chang SM, Phillips JJ, Molinaro AM, Costello JF, Mazor T, Alexandrescu S, Lupo JM, Nelson SJ, Berger M, Prados M, Taylor JW, Butowski N, Clarke JL, Haas-Kogan D
• A phase 1 trial of intravenous liposomal irinotecan in patients with recurrent high-grade glioma.
  Cancer chemotherapy and pharmacology 2017 Clarke JL, Molinaro AM, Cabrera JR, DeSilva AA, Rabbitt JE, Prey J, Drummond DC, Kim J, Noble C, Fitzgerald JB, Chang SM, Butowski NA, Taylor JW, Park JW, Prados MD
• Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide.
  Neuro-oncology 2017 Wahl M, Phillips JJ, Molinaro AM, Lin Y, Perry A, Haas-Kogan DA, Costello JF, Dayal M, Butowski N, Clarke JL, Prados M, Nelson S, Berger MS, Chang SM
• Glioma FMISO PET/MR Imaging Concurrent with Antiangiogenic Therapy: Molecular Imaging as a Clinical Tool in the Burgeoning Era of Personalized Medicine.
  Biomedicines 2016 Barajas RF, Krohn KA, Link JM, Hawkins RA, Clarke JL, Pampaloni MH, Cha S
• Histopathologic review of pineal parenchymal tumors identifies novel morphologic subtypes and prognostic factors for outcome.
  Neuro-oncology 2016 Raleigh DR, Solomon DA, Lloyd SA, Lazar A, Garcia MA, Sneed PK, Clarke JL, McDermott MW, Berger MS, Tihan T, Haas-Kogan DA
• Case-Based Review: meningioma.
  Neuro-oncology practice 2016 Fogh SE, Johnson DR, Barker FG, Brastianos PK, Clarke JL, Kaufmann TJ, Oberndorfer S, Preusser M, Raghunathan A, Santagata S, Theodosopoulos PV
• Clinical outcome and prognostic factors for central neurocytoma: twenty year institutional experience.
  Journal of neuro-oncology 2016 Imber BS, Braunstein SE, Wu FY, Nabavizadeh N, Boehling N, Weinberg VK, Tihan T, Barnes M, Mueller S, Butowski NA, Clarke JL, Chang SM, McDermott MM, Prados MD, Berger MS, Haas-Kogan DA
• Impact of Timing of Concurrent Chemoradiation for Newly Diagnosed Glioblastoma: A Critical Review of Current Evidence.
  Neurosurgery 2015 Han SJ, Englot DJ, Birk H, Molinaro AM, Chang SM, Clarke JL, Prados MD, Taylor JW, Berger MS, Butowski NA
• The Effect of Timing of Concurrent Chemoradiation in Patients With Newly Diagnosed Glioblastoma.
  Neurosurgery 2015 Han SJ, Rutledge WC, Molinaro AM, Chang SM, Clarke JL, Prados MD, Taylor JW, Berger MS, Butowski NA
• Case-Based Review: newly diagnosed glioblastoma.
  Neuro-oncology practice 2015 Johnson DR, Fogh SE, Giannini C, Kaufmann TJ, Raghunathan A, Theodosopoulos PV, Clarke JL
• Assessing Biological Response to Bevacizumab Using 18F-Fluoromisonidazole PET/MR Imaging in a Patient with Recurrent Anaplastic Astrocytoma.
  Case reports in radiology 2015 Barajas RF, Pampaloni MH, Clarke JL, Seo Y, Savic D, Hawkins RA, Behr SC, Chang SM, Berger M, Dillon WP, Cha S
• Bevacizumab and other targeted agents in the upfront treatment of glioblastoma.
  Seminars in radiation oncology 2014 Clarke JL
• Standardization and quality assurance of radiation therapy volumes for adults with high-grade gliomas.
  Seminars in radiation oncology 2014 Fogh S, Wahl M, Anwar M, Haas-Kogan D, Clarke JL, Sneed PK
• Familial gliomas: cases in two pairs of brothers.
  Journal of neuro-oncology 2014 Osorio JA, Hervey-Jumper SL, Walsh KM, Clarke JL, Butowski NA, Prados MD, Berger MS
• Process evaluation design in a cluster randomised controlled childhood obesity prevention trial: the WAVES study.
  The international journal of behavioral nutrition and physical activity 2014 Griffin TL, Pallan MJ, Clarke JL, Lancashire ER, Lyon A, Parry JM, Adab P, WAVES study trial investigators
• A single-institution phase II trial of radiation, temozolomide, erlotinib, and bevacizumab for initial treatment of glioblastoma.
  Neuro-oncology 2014 Clarke JL, Molinaro AM, Phillips JJ, Butowski NA, Chang SM, Perry A, Costello JF, DeSilva AA, Rabbitt JE, Prados MD
• Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma.
  Neuro-oncology 2014 Han SJ, Rolston JD, Molinaro AM, Clarke JL, Prados MD, Chang SM, Berger MS, DeSilva A, Butowski NA
• Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial.
  Neuro-oncology 2013 Bloch O, Crane CA, Fuks Y, Kaur R, Aghi MK, Berger MS, Butowski NA, Chang SM, Clarke JL, McDermott MW, Prados MD, Sloan AE, Bruce JN, Parsa AT
• Relationship of glioblastoma multiforme to the subventricular zone is associated with survival.
  Neuro-oncology 2012 Jafri NF, Clarke JL, Weinberg V, Barani IJ, Cha S
• Neoplastic myelopathy.
  Seminars in neurology 2012 Nagpal S, Clarke JL
• Leptomeningeal metastasis from systemic cancer.
  Continuum (Minneapolis, Minn.) 2012 Clarke JL
• Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy.
  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2012 Morris PG, Reiner AS, Szenberg OR, Clarke JL, Panageas KS, Perez HR, Kris MG, Chan TA, DeAngelis LM, Omuro AM
• Neurosurgical management and prognosis of patients with glioblastoma that progresses during bevacizumab treatment.
  Neurosurgery 2012 Clark AJ, Lamborn KR, Butowski NA, Chang SM, Prados MD, Clarke JL, McDermott MW, Parsa AT, Berger MS, Aghi MK
• Neuroimaging: diagnosis and response assessment in glioblastoma.
  Cancer journal (Sudbury, Mass.) 2012 Clarke JL, Chang SM
• Primary central nervous system lymphoma.
  Handbook of clinical neurology 2012 Clarke JL, Deangelis LM
• Conditional probability of survival in patients with newly diagnosed glioblastoma.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011 Polley MY, Lamborn KR, Chang SM, Butowski N, Clarke JL, Prados M
• "Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer.
  Neuro-oncology 2011 Grommes C, Oxnard GR, Kris MG, Miller VA, Pao W, Holodny AI, Clarke JL, Lassman AB
• Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma?
  Neuro-oncology 2011 Clarke JL, Ennis MM, Yung WK, Chang SM, Wen PY, Cloughesy TF, Deangelis LM, Robins HI, Lieberman FS, Fine HA, Abrey L, Gilbert MR, Mehta M, Kuhn JG, Aldape KD, Lamborn KR, Prados MD, North American …
• High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer.
  Journal of neuro-oncology 2010 Clarke JL, Pao W, Wu N, Miller VA, Lassman AB
• Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide.
  Neuro-oncology 2009 Polley MY, Lamborn KR, Chang SM, Butowski N, Clarke JL, Prados M
• Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009 Clarke JL, Iwamoto FM, Sul J, Panageas K, Lassman AB, DeAngelis LM, Hormigo A, Nolan CP, Gavrilovic I, Karimi S, Abrey LE
• Pseudoprogression and pseudoresponse: challenges in brain tumor imaging.
  Current neurology and neuroscience reports 2009 Clarke JL, Chang S
• External validation of the ICH score.
  Neurocritical care 2004 Clarke JL, Johnston SC, Farrant M, Bernstein R, Tong D, Hemphill JC